{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:19:07Z","timestamp":1794939547325,"version":"4.9.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0526"],"award-info":[{"award-number":["W81XWH-18-1-0526"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA171189"],"award-info":[{"award-number":["R01CA171189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced prostate cancer (PCa) often develops bone metastasis, for which therapies are very limited and the underlying mechanisms are poorly understood. We report that bone-borne TGF-\u03b2 induces the acetylation of transcription factor KLF5 in PCa bone metastases, and acetylated KLF5 (Ac-KLF5) causes osteoclastogenesis and bone metastatic lesions by activating CXCR4, which leads to IL-11 secretion, and stimulating SHH\/IL-6 paracrine signaling. While essential for maintaining the mesenchymal phenotype and tumorigenicity, Ac-KLF5 also causes resistance to docetaxel in tumors and bone metastases, which is overcome by targeting CXCR4 with FDA-approved plerixafor. Establishing a mechanism for bone metastasis and chemoresistance in PCa, these findings provide a rationale for treating chemoresistant bone metastasis of PCa with inhibitors of Ac-KLF5\/CXCR4 signaling.<\/jats:p>","DOI":"10.1038\/s41467-021-21976-w","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T07:03:23Z","timestamp":1615964603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6586-4016","authenticated-orcid":false,"given":"Baotong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ping","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeboye O.","family":"Osunkoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2019","authenticated-orcid":false,"given":"Paula M.","family":"Vertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6783-9957","authenticated-orcid":false,"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-5782","authenticated-orcid":false,"given":"Jin-Tang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"21976_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"21976_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby, M., Hirst, C. & Crawford, E. D. Characterising the castration-resistant prostate cancer population: a systematic review. Int. J. Clin. Pract. 65, 1180\u20131192 (2011).","journal-title":"Int. J. Clin. Pract."},{"key":"21976_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325\u2013334 (2015).","journal-title":"Eur. Urol."},{"key":"21976_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578\u2013583 (2000).","journal-title":"Hum. Pathol."},{"key":"21976_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein, A. L. et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317, 48\u201358 (2017).","journal-title":"JAMA"},{"key":"21976_CR6","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 31, 3800\u20133806 (2013).","journal-title":"J. Clin. Oncol."},{"key":"21976_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1756287216686018","volume":"9","author":"M Hegemann","year":"2017","unstructured":"Hegemann, M., Bedke, J., Stenzl, A. & Todenhofer, T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther. Adv. Urol. 9, 81\u201388 (2017).","journal-title":"Ther. Adv. Urol."},{"key":"21976_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrurol.2015.90","volume":"12","author":"JJ Body","year":"2015","unstructured":"Body, J. J., Casimiro, S. & Costa, L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat. Rev. Urol. 12, 340\u2013356 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"21976_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James, N. D. et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019). Eur. Urol. 67, 1028\u20131038 (2015).","journal-title":"Eur. Urol."},{"key":"21976_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eursup.2004.09.001","volume":"3","author":"P-A Abrahamsson","year":"2004","unstructured":"Abrahamsson, P.-A. Pathophysiology of bone metastases in prostate cancer. Eur. Urol. Suppl. 3, 3\u20139 (2004).","journal-title":"Eur. Urol. Suppl."},{"key":"21976_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MOU.0b013e32835e9edc","volume":"23","author":"C Morisson","year":"2013","unstructured":"Morisson, C., Jeraj, R. & Liu, G. Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers. Curr. Opin. Urol. 23, 230\u2013236 (2013).","journal-title":"Curr. Opin. Urol."},{"key":"21976_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jcb.10662","volume":"91","author":"ET Keller","year":"2004","unstructured":"Keller, E. T. & Brown, J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell Biochem. 91, 718\u2013729 (2004).","journal-title":"J. Cell Biochem."},{"key":"21976_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","volume":"16","author":"PI Croucher","year":"2016","unstructured":"Croucher, P. I., McDonald, M. M. & Martin, T. J. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer 16, 373\u2013386 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"21976_CR14","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1172\/JCI26239","volume":"115","author":"TJ Martin","year":"2005","unstructured":"Martin, T. J. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J. Clin. Invest. 115, 2322\u20132324 (2005).","journal-title":"J. Clin. Invest."},{"key":"21976_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u2013425 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"21976_CR16","doi-asserted-by":"crossref","unstructured":"Guise T. A. & Chirgwin J. M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin. Orthop. Relat. Res. 415(Suppl), S32\u2013S38 (2003).","DOI":"10.1097\/01.blo.0000093055.96273.69"},{"key":"21976_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","volume":"80","author":"TA Guise","year":"1997","unstructured":"Guise, T. A. Parathyroid hormone-related protein and bone metastases. Cancer 80, 1572\u20131580 (1997).","journal-title":"Cancer"},{"key":"21976_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1026404227624","volume":"17","author":"WC Duivenvoorden","year":"1999","unstructured":"Duivenvoorden, W. C., Hirte, H. W. & Singh, G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin. Exp. Metastasis 17, 27\u201334 (1999).","journal-title":"Clin. Exp. Metastasis"},{"key":"21976_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/07357907.2012.692171","volume":"30","author":"H Ye","year":"2012","unstructured":"Ye, H. et al. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 30, 513\u2013518 (2012).","journal-title":"Cancer Invest."},{"key":"21976_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7150\/ijbs.4564","volume":"8","author":"EC Connolly","year":"2012","unstructured":"Connolly, E. C., Freimuth, J. & Akhurst, R. J. Complexities of TGF-beta targeted cancer therapy. Int. J. Biol. Sci. 8, 964\u2013978 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"21976_CR21","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Dev. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Dev. Ther."},{"key":"21976_CR22","first-page":"90","volume":"3","author":"S Sethi","year":"2010","unstructured":"Sethi, S., Macoska, J., Chen, W. & Sarkar, F. H. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 3, 90\u201399 (2010).","journal-title":"Am. J. Transl. Res."},{"key":"21976_CR23","first-page":"683","volume":"4","author":"AB Roberts","year":"1985","unstructured":"Roberts, A. B. & Sporn, M. B. Transforming growth factors. Cancer Surv. 4, 683\u2013705 (1985).","journal-title":"Cancer Surv."},{"key":"21976_CR24","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1073\/pnas.1633291100","volume":"100","author":"AB Roberts","year":"2003","unstructured":"Roberts, A. B. & Wakefield, L. M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl Acad. Sci. USA 100, 8621\u20138623 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21976_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGFbeta in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"21976_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massague","year":"2012","unstructured":"Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616\u2013630 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"21976_CR27","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13, 788\u2013799 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"21976_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2853","volume":"10","author":"H Ikushima","year":"2010","unstructured":"Ikushima, H. & Miyazono, K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 10, 415\u2013424 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"21976_CR29","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. & Hata, A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790\u2013811 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21976_CR30","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Transforming growth factor beta mediates drug resistance by regulating expression of pyruvate dehydrogenase kinase 4 in colorectal cancer. J. Biol. Chem. 291, 17405\u201316 (2016).","DOI":"10.1074\/jbc.M116.713735"},{"key":"21976_CR31","doi-asserted-by":"publisher","first-page":"e0145985","DOI":"10.1371\/journal.pone.0145985","volume":"11","author":"T Sakamoto","year":"2016","unstructured":"Sakamoto, T. et al. A histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer. PLoS ONE 11, e0145985 (2016).","journal-title":"PLoS ONE"},{"key":"21976_CR32","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1172\/JCI65416","volume":"123","author":"NE Bhola","year":"2013","unstructured":"Bhola, N. E. et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348\u20131358 (2013).","journal-title":"J. Clin. Invest."},{"key":"21976_CR33","first-page":"799","volume":"32","author":"YJ Kim","year":"2012","unstructured":"Kim, Y. J., Hwang, J. S., Hong, Y. B., Bae, I. & Seong, Y. S. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res. 32, 799\u2013806 (2012).","journal-title":"Anticancer Res."},{"key":"21976_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1535-7163.MCT-11-0289","volume":"11","author":"M Marin-Aguilera","year":"2012","unstructured":"Marin-Aguilera, M. et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol. Cancer Ther. 11, 329\u2013339 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"21976_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704\u2013715 (2008).","journal-title":"Cell"},{"key":"21976_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak, S. & Ten Dijke, P. Targeting TGF-beta signaling in cancer. Trends Cancer 3, 56\u201371 (2017).","journal-title":"Trends Cancer"},{"key":"21976_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1517\/14728222.2013.782287","volume":"17","author":"LH Katz","year":"2013","unstructured":"Katz, L. H. et al. Targeting TGF-beta signaling in cancer. Expert Opin. Ther. Targets 17, 743\u2013760 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"21976_CR38","doi-asserted-by":"publisher","first-page":"18184","DOI":"10.1074\/jbc.M109.007096","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo, P., Zhao, K. W., Dong, X. Y., Sun, X. & Dong, J. T. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. J. Biol. Chem. 284, 18184\u201318193 (2009).","journal-title":"J. Biol. Chem."},{"key":"21976_CR39","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1074\/jbc.M806270200","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo, P. et al. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J. Biol. Chem. 284, 6071\u20136078 (2009).","journal-title":"J. Biol. Chem."},{"key":"21976_CR40","doi-asserted-by":"publisher","first-page":"28243","DOI":"10.1074\/jbc.M109.036160","volume":"284","author":"P Guo","year":"2009","unstructured":"Guo, P. et al. Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta. J. Biol. Chem. 284, 28243\u201328252 (2009).","journal-title":"J. Biol. Chem."},{"key":"21976_CR41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ijc.29028","volume":"136","author":"X Li","year":"2015","unstructured":"Li, X. et al. Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int. J. Cancer 136, 536\u2013546 (2015).","journal-title":"Int. J. Cancer"},{"key":"21976_CR42","doi-asserted-by":"crossref","unstructured":"Zhang, B., et al. Klf5 acetylation regulates luminal differentiation of basal progenitors in prostate development and regeneration. Nat. Commun. 11, 997 (2020).","DOI":"10.1038\/s41467-020-14737-8"},{"key":"21976_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","volume":"11","author":"BA Gartrell","year":"2014","unstructured":"Gartrell, B. A. & Saad, F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat. Rev. Clin. Oncol. 11, 335\u2013345 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21976_CR44","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ccell.2015.04.009","volume":"27","author":"PG Fournier","year":"2015","unstructured":"Fournier, P. G. et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 27, 809\u2013821 (2015).","journal-title":"Cancer Cell"},{"key":"21976_CR45","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2217\/fon.09.90","volume":"5","author":"MK Wendt","year":"2009","unstructured":"Wendt, M. K., Allington, T. M. & Schiemann, W. P. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 5, 1145\u20131168 (2009).","journal-title":"Future Oncol."},{"key":"21976_CR46","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1128\/MCB.00787-13","volume":"33","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. Mol. Cell. Biol. 33, 4919\u20134935 (2013).","journal-title":"Mol. Cell. Biol."},{"key":"21976_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ccell.2017.02.003","volume":"31","author":"JB Wu","year":"2017","unstructured":"Wu, J. B. et al. MAOA-dependent activation of Shh-IL6-RANKL signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions. Cancer Cell 31, 368\u2013382 (2017).","journal-title":"Cancer Cell"},{"key":"21976_CR48","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.4049\/jimmunol.145.10.3297","volume":"145","author":"Y Ishimi","year":"1990","unstructured":"Ishimi, Y. et al. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145, 3297\u20133303 (1990).","journal-title":"J. Immunol."},{"key":"21976_CR49","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s00018-009-0045-z","volume":"66","author":"JT Dong","year":"2009","unstructured":"Dong, J. T. & Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol. Life Sci. 66, 2691\u20132706 (2009).","journal-title":"Cell Mol. Life Sci."},{"key":"21976_CR50","doi-asserted-by":"publisher","first-page":"8528","DOI":"10.1128\/MCB.23.23.8528-8541.2003","volume":"23","author":"S Miyamoto","year":"2003","unstructured":"Miyamoto, S. et al. Positive and negative regulation of the cardiovascular transcription factor KLF5 by p300 and the oncogenic regulator SET through interaction and acetylation on the DNA-binding domain. Mol. Cell Biol. 23, 8528\u20138541 (2003).","journal-title":"Mol. Cell Biol."},{"key":"21976_CR51","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/cr.2011.34","volume":"21","author":"B Zheng","year":"2011","unstructured":"Zheng, B. et al. HDAC2 phosphorylation-dependent Klf5 deacetylation and RARalpha acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs. Cell Res. 21, 1487\u20131508 (2011).","journal-title":"Cell Res."},{"key":"21976_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0552-0","volume":"15","author":"MK Conley-LaComb","year":"2016","unstructured":"Conley-LaComb, M. K. et al. Pharmacological targeting of CXCL12\/CXCR4 signaling in prostate cancer bone metastasis. Mol. Cancer 15, 68 (2016).","journal-title":"Mol. Cancer"},{"key":"21976_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1541-7786.MCR-07-0117","volume":"6","author":"SR Chinni","year":"2008","unstructured":"Chinni, S. R. et al. CXCL12\/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 6, 446\u2013457 (2008).","journal-title":"Mol. Cancer Res."},{"key":"21976_CR54","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1172\/JCI117130","volume":"93","author":"G Girasole","year":"1994","unstructured":"Girasole, G., Passeri, G., Jilka, R. L. & Manolagas, S. C. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Invest. 93, 1516\u20131524 (1994).","journal-title":"J. Clin. Invest."},{"key":"21976_CR55","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1084\/jem.183.6.2581","volume":"183","author":"E Romas","year":"1996","unstructured":"Romas, E. et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med. 183, 2581\u20132591 (1996).","journal-title":"J. Exp. Med."},{"key":"21976_CR56","first-page":"2209","volume":"30","author":"L Xie","year":"2010","unstructured":"Xie, L. et al. CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer. Anticancer Res. 30, 2209\u20132216 (2010).","journal-title":"Anticancer Res."},{"key":"21976_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ijc.25665","volume":"129","author":"S Hassan","year":"2011","unstructured":"Hassan, S. et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer 129, 225\u2013232 (2011).","journal-title":"Int. J. Cancer"},{"key":"21976_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1593\/neo.12324","volume":"14","author":"UM Domanska","year":"2012","unstructured":"Domanska, U. M. et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14, 709\u2013718 (2012).","journal-title":"Neoplasia"},{"key":"21976_CR59","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.7150\/thno.44567","volume":"10","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. TGF-beta causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics 10, 7656\u20137670 (2020).","journal-title":"Theranostics"},{"key":"21976_CR60","doi-asserted-by":"publisher","first-page":"e0138168","DOI":"10.1371\/journal.pone.0138168","volume":"10","author":"T Zhao","year":"2015","unstructured":"Zhao, T., Liu, C. & Chen, L. Roles of Klf5 acetylation in the self-renewal and the differentiation of mouse embryonic stem cells. PLoS One 10, e0138168 (2015).","journal-title":"PLoS One"},{"key":"21976_CR61","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbrc.2018.04.153","volume":"500","author":"R Tao","year":"2018","unstructured":"Tao, R. et al. HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation. Biochem. Biophys. Res. Commun. 500, 777\u2013782 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"21976_CR62","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1242\/dev.126.19.4267","volume":"126","author":"E Filvaroff","year":"1999","unstructured":"Filvaroff, E. et al. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126, 4267\u20134279 (1999).","journal-title":"Development"},{"key":"21976_CR63","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","volume":"19","author":"GD Roodman","year":"2001","unstructured":"Roodman, G. D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19, 3562\u20133571 (2001).","journal-title":"J. Clin. Oncol."},{"key":"21976_CR64","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley, L. A., Fournier, P. G., Chirgwin, J. M. & Guise, T. A. Molecular biology of bone metastasis. Mol. Cancer Ther. 6, 2609\u20132617 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"21976_CR65","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2174\/138161210791034012","volume":"16","author":"AC Hirbe","year":"2010","unstructured":"Hirbe, A. C., Morgan, E. A. & Weilbaecher, K. N. The CXCR4\/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr. Pharm. Des. 16, 1284\u20131290 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"21976_CR66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1440-1827.2010.02548.x","volume":"60","author":"B Furusato","year":"2010","unstructured":"Furusato, B., Mohamed, A., Uhlen, M. & Rhim, J. S. CXCR4 and cancer. Pathol. Int 60, 497\u2013505 (2010).","journal-title":"Pathol. Int"},{"key":"21976_CR67","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","volume":"16","author":"BA Teicher","year":"2010","unstructured":"Teicher, B. A. & Fricker, S. P. CXCL12 (SDF-1)\/CXCR4 pathway in cancer. Clin. Cancer Res 16, 2927\u20132931 (2010).","journal-title":"Clin. Cancer Res"},{"key":"21976_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1594-1","volume":"10","author":"M Liang","year":"2019","unstructured":"Liang, M. et al. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis. Cell Death Dis. 10, 353 (2019).","journal-title":"Cell Death Dis."},{"key":"21976_CR69","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ceb.2009.01.021","volume":"21","author":"CH Heldin","year":"2009","unstructured":"Heldin, C. H., Landstrom, M. & Moustakas, A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21, 166\u2013176 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"21976_CR70","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1101\/gad.225334.113","volume":"27","author":"JH Tsai","year":"2013","unstructured":"Tsai, J. H. & Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192\u20132206 (2013).","journal-title":"Genes Dev."},{"key":"21976_CR71","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-13-0775","volume":"13","author":"M Marin-Aguilera","year":"2014","unstructured":"Marin-Aguilera, M. et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol. Cancer Ther. 13, 1270\u20131284 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"21976_CR72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/bonekey.2012.96","volume":"1","author":"JT Buijs","year":"2012","unstructured":"Buijs, J. T., Stayrook, K. R. & Guise, T. A. The role of TGF-beta in bone metastasis: novel therapeutic perspectives. Bonekey Rep. 1, 96 (2012).","journal-title":"Bonekey Rep."},{"key":"21976_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bone.2010.08.004","volume":"48","author":"P Juarez","year":"2011","unstructured":"Juarez, P. & Guise, T. A. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone 48, 23\u201329 (2011).","journal-title":"Bone"},{"key":"21976_CR74","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/hum.2012.040","volume":"23","author":"Z Hu","year":"2012","unstructured":"Hu, Z. et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther. 23, 871\u2013882 (2012).","journal-title":"Hum. Gene Ther."},{"key":"21976_CR75","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.bone.2011.11.022","volume":"50","author":"X Wan","year":"2012","unstructured":"Wan, X. et al. Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone 50, 695\u2013703 (2012).","journal-title":"Bone"},{"key":"21976_CR76","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cpr.12043","volume":"46","author":"Z Dong","year":"2013","unstructured":"Dong, Z., Yang, L. & Lai, D. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression. Cell Prolif. 46, 425\u2013435 (2013).","journal-title":"Cell Prolif."},{"key":"21976_CR77","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.14315","volume":"6","author":"R Liu","year":"2016","unstructured":"Liu, R. et al. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics 6, 533\u2013544 (2016).","journal-title":"Theranostics"},{"key":"21976_CR78","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/15384047.2015.1070992","volume":"16","author":"O Maehara","year":"2015","unstructured":"Maehara, O. et al. A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol. Ther. 16, 1453\u20131461 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"21976_CR79","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2016.01.009","volume":"164","author":"CJ David","year":"2016","unstructured":"David, C. J. et al. TGF-beta Tumor Suppression through a Lethal EMT. Cell 164, 1015\u20131030 (2016).","journal-title":"Cell"},{"key":"21976_CR80","doi-asserted-by":"publisher","first-page":"11490","DOI":"10.18632\/oncotarget.2571","volume":"5","author":"A Bhardwaj","year":"2014","unstructured":"Bhardwaj, A. et al. CXCL12\/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget 5, 11490\u201311500 (2014).","journal-title":"Oncotarget"},{"key":"21976_CR81","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"21976_CR82","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1038\/sj.onc.1208497","volume":"24","author":"C Chen","year":"2005","unstructured":"Chen, C. et al. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24, 3319\u20133327 (2005).","journal-title":"Oncogene"},{"key":"21976_CR83","doi-asserted-by":"publisher","first-page":"e65538","DOI":"10.1371\/journal.pone.0065538","volume":"8","author":"C Xing","year":"2013","unstructured":"Xing, C. et al. Different expression patterns and functions of acetylated and unacetylated Klf5 in the proliferation and differentiation of prostatic epithelial cells. PLoS One 8, e65538 (2013).","journal-title":"PLoS One"},{"key":"21976_CR84","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"21976_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"21976_CR86","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"21976_CR87","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/ni.3519","volume":"17","author":"BG Barwick","year":"2016","unstructured":"Barwick, B. G., Scharer, C. D., Bally, A. P. R. & Boss, J. M. Plasma cell differentiation is coupled to division-dependent DNA hypomethylation and gene regulation. Nat. Immunol. 17, 1216\u20131225 (2016).","journal-title":"Nat. Immunol."},{"key":"21976_CR88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"21976_CR89","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"21976_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21976-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21976-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21976-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T04:29:45Z","timestamp":1698035385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21976-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21976"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21976-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1714"}}